Collegium Pharmaceutical (COLL) Stock Price, News & Analysis

Company Overview

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on developing and commercializing medicines for patients with central nervous system disorders. The company’s portfolio includes treatments for pain and attention deficit hyperactivity disorder (ADHD), with an emphasis on products that address unmet patient and healthcare-provider needs.

Collegium’s pain portfolio includes Xtampza ER, an extended-release oxycodone product designed with abuse-deterrent properties; Nucynta and Nucynta ER, which contain tapentadol and are used to treat certain types of acute and chronic pain; and Belbuca, a buprenorphine buccal film for the management of chronic pain. These products are marketed primarily in the United States.

The company expanded beyond pain management through its acquisition of Ironshore Therapeutics, adding a portfolio of ADHD medicines that includes Jornay PM, Mydayis, Quillivant XR, Quillichew ER, Dyanavel XR and Evekeo ODT. Collegium was founded in 2002 and is headquartered in Stoughton, Massachusetts. It sells its products through commercial and specialty-pharmacy channels and works with healthcare professionals and patients throughout the U.S.

Key Stats

• Today's Range: $21.90 to $22.77
• 50-Day Range: $21.84 to $36.29
• 52-Week Range: $21.65 to $50.79
• Volume: 650,109 shs
• Average Volume: 563,925 shs
• Market Capitalization: $737.07 million
• P/E Ratio: 18.26
• Dividend Yield: N/A
• Price Target: $48.71
• Consensus Rating: Moderate Buy

Collegium Pharmaceutical Stock Analysis - MarketRank™

Collegium Pharmaceutical scored higher than 66% of companies evaluated by MarketBeat, and ranked 259th out of 901 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Collegium Pharmaceutical has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Collegium Pharmaceutical has a consensus price target of $48.71, representing about 115.2% upside from its current price of $22.64.

Amount of Analyst Coverage

Collegium Pharmaceutical has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -27.95%

Earnings Growth

Earnings for Collegium Pharmaceutical are expected to decrease by -27.95% in the coming year, from $6.19 to $4.46 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Collegium Pharmaceutical is 18.25, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.93.

Price to Earnings Ratio vs. Sector

The P/E ratio of Collegium Pharmaceutical is 18.25, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.16.

Price to Book Value per Share Ratio

Collegium Pharmaceutical has a P/B Ratio of 2.37. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

18.98% of the float of Collegium Pharmaceutical has been sold short.

Short Interest Ratio / Days to Cover

Collegium Pharmaceutical has a short interest ratio ("days to cover") of 8.08.

Change versus previous month

Short interest in Collegium Pharmaceutical has recently decreased by 7.04%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Collegium Pharmaceutical does not currently pay a dividend.

Dividend Growth

Collegium Pharmaceutical does not have a long track record of dividend growth.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.16

News Sentiment

Collegium Pharmaceutical has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Collegium Pharmaceutical this week, compared to 4 articles on an average week.

Search Interest

Only 4 people have searched for COLL on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

Only 1 people have added Collegium Pharmaceutical to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Collegium Pharmaceutical insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.85% of the stock of Collegium Pharmaceutical is held by insiders.

Percentage Held by Institutions

Collegium Pharmaceutical has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/24/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:COLL
• CIK: 1267565
• Web: www.collegiumpharma.com
• Phone: (781) 713-3699
• Fax: N/A
• Employees: 423
• Year Founded: 2002

Price Target and Rating

• Average Price Target for Collegium Pharmaceutical: $48.71
• High Price Target: $60.00
• Low Price Target: $43.00
• Potential Upside/Downside: +115.2%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.24
• Trailing P/E Ratio: 18.26
• Forward P/E Ratio: 3.66
• P/E Growth: N/A
• Net Income: $62.87 million
• Net Margins: 5.93%
• Pretax Margin: 9.61%
• Return on Equity: 91.43%
• Return on Assets: 15.57%

Debt

• Debt-to-Equity Ratio: 3.32
• Current Ratio: 1.03
• Quick Ratio: 0.84

Sales & Book Value

• Annual Sales: $808.21 million
• Price / Sales: 0.91
• Cash Flow: $15.09 per share
• Price / Cash Flow: 1.50
• Book Value: $9.54 per share
• Price / Book: 2.37

Miscellaneous

• Outstanding Shares: 32,556,000
• Free Float: 31,954,000
• Market Cap: $737.07 million
• Optionable: Optionable
• Beta: 0.72